VENLAFAXINE HYDROCHLORIDE

Manufacturer: Annora Pharma Private Limited

Score: 148.0

Quick Summary

Venlafaxine Hydrochloride is a serotonin and norepinephrine reuptake inhibitor (SNRI) used for the treatment of Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), and Panic Disorder (PD). The recommended starting dose is 75 mg per day, administered in a single dose, with a maximum dose of 225 mg per day. It is essential to monitor patients for clinical worsening, suicidal thoughts, and behaviors, especially during the initial few months of treatment or when the dose is changed. The drug has several contraindications, including hypersensitivity to venlafaxine hydrochloride, and use with monoamine oxidase inhibitors (MAOIs). Special population considerations, such as use during pregnancy, nursing mothers, pediatric use, and geriatric use, are also crucial to ensure safe and effective treatment.

Key Clinical Findings and Indications

Major Depressive Disorder (MDD)
Generalized Anxiety Disorder (GAD)
Social Anxiety Disorder (SAD)
Panic Disorder (PD)

Important Safety Information

Warning

Increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults

Contraindications

Hypersensitivity to venlafaxine hydrochloride
Use with monoamine oxidase inhibitors (MAOIs)

Adverse Reactions

Nausea
Somnolence
Dry mouth
Sweating
Abnormal ejaculation
Anorexia
Constipation
Erectile dysfunction
Libido decreased

Dosing Recommendations

Nursing Mothers

Venlafaxine and ODV have been reported to be excreted in human milk

Pediatric Use

Not recommended for pediatric patients due to lack of efficacy and potential adverse effects

Geriatric Use

No overall differences in effectiveness or safety were observed between geriatric patients and younger patients